WAVE Life Sciences Ltd.
WVE
$6.73
-$0.06-0.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1,191.04% | -138.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,191.04% | -138.98% | |||
| Cost of Revenue | 8.37% | 1.99% | |||
| Gross Profit | 180.01% | -136.09% | |||
| SG&A Expenses | 7.27% | 5.22% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.08% | 2.83% | |||
| Operating Income | 135.93% | -82.63% | |||
| Income Before Tax | 147.35% | -87.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 147.35% | -87.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 147.35% | -87.65% | |||
| EBIT | 135.93% | -82.63% | |||
| EBITDA | 137.92% | -85.21% | |||
| EPS Basic | 138.86% | -83.32% | |||
| Normalized Basic EPS | 138.86% | -83.32% | |||
| EPS Diluted | 136.49% | -84.89% | |||
| Normalized Diluted EPS | 136.42% | -83.32% | |||
| Average Basic Shares Outstanding | 21.82% | 2.34% | |||
| Average Diluted Shares Outstanding | 29.97% | 2.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||